Geron (NASDAQ:GERN) Shares Down 4.2% - What's Next?

Geron Corporation (NASDAQ:GERN - Get Free Report) shares dropped 4.2% during trading on Wednesday . The stock traded as low as $1.49 and last traded at $1.49. Approximately 610,948 shares changed hands during trading, a decline of 95% from the average daily volume of 11,166,345 shares. The stock had previously closed at $1.55.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Stifel Nicolaus decreased their price objective on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Scotiabank cut shares of Geron from a "sector outperform" rating to a "sector perform" rating and reduced their target price for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $5.00 price target on shares of Geron in a research note on Wednesday, March 12th. Barclays restated an "overweight" rating and issued a $4.00 price objective (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Geron has a consensus rating of "Moderate Buy" and an average target price of $5.06.

Geron Stock Down 2.3%

The firm has a 50-day simple moving average of $1.42 and a 200 day simple moving average of $2.15. The company has a debt-to-equity ratio of 0.44, a current ratio of 7.87 and a quick ratio of 6.97. The company has a market capitalization of $964.93 million, a PE ratio of -7.17 and a beta of 0.69.

Geron (NASDAQ:GERN - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 47.86% and a negative net margin of 119.54%. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. During the same quarter last year, the firm earned ($0.07) EPS. The business's revenue was up 12927.3% on a year-over-year basis. On average, research analysts predict that Geron Corporation will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

A number of hedge funds have recently added to or reduced their stakes in GERN. Xponance Inc. increased its holdings in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock worth $150,000 after acquiring an additional 4,829 shares during the period. SBI Securities Co. Ltd. bought a new position in Geron in the 4th quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company's stock valued at $627,000 after purchasing an additional 8,123 shares during the period. Frisch Financial Group Inc. raised its holdings in shares of Geron by 84.3% during the first quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 8,700 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in Geron by 33.1% in the 4th quarter. HighTower Advisors LLC now owns 36,041 shares of the biopharmaceutical company's stock worth $128,000 after buying an additional 8,967 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.